natgillin/translations-raw huggingface dataset:
The effects of Reasanz were first tested in experimental models before being studied in humans. 
Učinki zdravila Reasanz so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The company that applied for authorisation is Novartis Europharm Ltd. 
Vlogo za pridobitev dovoljenja je predložila družba Novartis Europharm Ltd.
Refusal of the marketing authorisation for Reasanz (serelaxin) EMA/299385/2014 
Zavrnitev vloge za dovoljenje za promet z zdravilom Reasanz (serelaksin) EMA/299385/2014
The results included assigned values for a number of patients who had died or had required additional treatment for worsening symptoms and whose actual data were not used. 
V rezultate so bile vključene pripisane vrednosti za številne bolnike, ki so umrli ali so potrebovali dodatno zdravljenje zaradi poslabšanja simptomov in katerih dejanski podatki niso bili uporabljeni.
Furthermore, the Committee had concerns about the way the effectiveness of the medicine in the study had been analysed. 
Poleg tega je imel pomisleke glede načina analize učinkovitosti zdravila v študiji.
On 23 January 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Reasanz, intended for the treatment of acute heart failure. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je 23. januarja 2014 sprejel negativno mnenje, s katerim je priporočil zavrnitev vloge za pridobitev dovoljenja za promet z zdravilom Reasanz, namenjenim za zdravljenje akutnega srčnega popuščanja.
Refusal of the marketing authorisation for Reasanz (serelaxin) 
Zavrnitev vloge za dovoljenje za promet z zdravilom Reasanz (serelaksin)
The active substance in Reasanz, serelaxin, is a recombinant form of relaxin-2, a hormone naturally found in the body. 
Zdravilna učinkovina v zdravilu Reasanz, serelaksin, je rekombinantna oblika relaksina-2, ki je naravno prisoten hormon v telesu.
Reasanz is a medicine that contains the active substance serelaxin. 
Reasanz je zdravilo, ki vsebuje zdravilno učinkovino serelaksin.
Recombinant means that it is produced by bacteria into which a gene (DNA) has been introduced that makes the bacteria able to produce the hormone. 
Rekombinanten pomeni, da ga izdelajo bakterije, v katere so vstavili gen (DNK), s pomočjo katerega lahko tvorijo ta hormon.
At the time of the initial evaluation, the CHMP noted that the study results did not demonstrate a benefit for short-term relief of dyspnoea over up to 24 hours, and although some benefit was shown over 5 days it was not clear how this was of clinical relevance. 
V času začetnega vrednotenja je odbor CHMP ugotovil, da rezultati študije niso potrdili koristi pri kratkoročni ublažitvi dispneje v največ 24 urah in da kljub temu, da se je po petih dneh pokazala določena korist, ni jasno, kakšen je njen klinični pomen.
Reasanz was expected to be used to treat the symptoms of acute heart failure (an episode of severe or worsening symptoms in patients in whom the heart cannot pump sufficient blood around the body). 
Zdravilo Reasanz naj bi se uporabljalo za zdravljenje simptomov akutnega srčnega popuščanja (epizode hudih simptomov ali poslabšanja simptomov pri bolnikih, pri katerih srce ne more načrpati dovolj krvi za celotno telo).
When serelaxin attaches to receptors for relaxin in the blood vessels, it causes these vessels to relax and widen. 
Ko se serelaksin veže na receptorje za relaksin v krvnih žilah, povzroči, da se žile sprostijo in razširijo.
In addition, the CHMP questioned whether the type of the background treatment given to patients in the two study groups might have influenced the results. 
Odbor je izrazil tudi pomislek, da je morda vrsta osnovnega zdravljenja, ki so ga prejemali bolniki v obeh proučevanih skupinah, vplivala na rezultate.
After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 22 May 2014. 
Po preučitvi podlage za to zahtevo je odbor CHMP ponovno pregledal prvotno mnenje in dne 22. maja 2014 potrdil zavrnitev vloge za dovoljenje za promet z zdravilom.
Therefore, although the safety of Reasanz seemed acceptable, the CHMP concluded that the benefits of Reasanz did not outweigh its risks and maintained its previous recommendation that the medicine be refused marketing authorisation. 
Zato je kljub temu, da je varnost zdravila Reasanz ocenil za sprejemljivo, zaključil, da koristi zdravila Reasanz ne odtehtajo z njim povezanih tveganj, in potrdil svoje prejšnje priporočilo, da se dovoljenje za promet z njim zavrne.
These symptoms include high blood pressure in the vessels leaving the lungs, leading to congestion (fluid build-up) and dyspnoea (shortness of breath). 
Simptomi vključujejo visok krvni tlak v žilah, ki izstopajo iz pljuč, kar povzroči zamašitev (nabiranje tekočin) in dispnejo (kratko sapo).
During the re-examination, the CHMP reviewed again the data from the only main study submitted and confirmed its opinion that the effectiveness of Reasanz had not been sufficiently demonstrated. 
Med postopkom ponovnega pregleda je odbor CHMP še enkrat pregledal podatke iz edine predložene glavne študije in potrdil mnenje, da učinkovitost zdravila Reasanz ni bila zadostno dokazana.
What is Reasanz? 
Kaj je zdravilo Reasanz?
pressure in the blood vessels and makes it easier for the heart to pump blood around the body, which helps to relieve the symptoms of acute heart failure. 
S tem se zniža tlak v krvnih žilah, zaradi česar srce lažje črpa kri po telesu, to pa pomaga ublažiti simptome akutnega srčnega popuščanja.
The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with Reasanz. 
Družba je odbor CHMP obvestila, da zavrnitev nima nobenih posledic za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Reasanz.
Since only one main study was included in the application, the CHMP concluded that further studies would be needed to confirm the effectiveness of Reasanz in the treatment of acute heart failure. 
Glede na to, da je bila v okviru vloge predložena samo ena glavna študija, je odbor CHMP zaključil, da so za potrditev učinkovitosti zdravila Reasanz pri zdravljenju akutnega srčnega popuščanja potrebne dodatne študije.
How is Reasanz expected to work? 
Kako naj bi zdravilo Reasanz delovalo?
What was Reasanz expected to be used for? 
Za kaj naj bi se zdravilo Reasanz uporabljalo?
Reasanz infusion was compared with placebo (a dummy treatment) as an addition to their other treatment. 
V njej so primerjali infuzijo zdravila Reasanz in placebo (zdravilo brez zdravilne učinkovine), ki so ju dodajali drugemu zdravilu.
It was to be available as a concentrate to be diluted and given by infusion (drip) into a vein. 
Na voljo naj bi bilo v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
Overall summary of the scientific evaluation of Tibolona Aristo and associated names (see Annex I) 
Splošni povzetek znanstvenega vrednotenja zdravila Tibolona Aristo in povezanih imen (glejte Prilogo I)
• the CHMP considered that the available data confirms that the results of the bioequivalence study are reliable and demonstrate the bioequivalence of the proposed products and the reference product the CHMP has recommended the granting of the marketing authorisations for which the summary of product characteristics, labelling and package leaflet remain as per the final versions achieved during the Coordination group procedure as mentioned in Annex III for Tibolona Aristo and associated names (see Annex I). 
je odbor CHMP priporočil odobritev dovoljenj za promet z zdravili, za katera povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo ostajajo enaki kot zadnje različice, pripravljene med postopkom usklajevalne skupine, kot je navedeno v Prilogi III za zdravilo Tibolona Aristo in povezana imena (glejte Prilogo I).
Infants and children 
Dojenčki in otroci
• Section 3: How to use X 
• Poglavje 3: Kako uporabljati zdravilo X
• third trimester of pregnancy 
• tretje trimesečje nosečnosti
Your doctor will tell you how to take <invented name>. 
Zdravnik vam bo povedal, kako jemati zdravilo <izmišljeno ime>.
Section 2: What you need to know before you use X This following wording should be reflected in this section. 
Poglavje 2: Kaj morate vedeti, preden boste uporabili zdravilo X V tem poglavju mora biti izraženo naslednje besedilo.
Existing wording should be amended as necessary. 
Obstoječe besedilo je treba ustrezno popraviti.
The existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below. 
Obstoječe informacije o zdravilu je treba spremeniti (vstaviti, zamenjati ali izbrisati besedilo, kot je primerno), tako da bodo izražale odobreno besedilo, ki je navedeno spodaj.
• Section 4.3 Contraindications 
• Poglavje 4.3 - Kontraindikacije
Text in strikethrough should be deleted from the summary of product characteristics, if present. 
Prečrtano besedilo je treba izbrisati iz povzetka glavnih značilnosti zdravila, če je prisotno.
<Invented name> will be given to you as injection into your vein or into muscle. 
Zdravilo <izmišljeno ime> boste prejeli v obliki injekcije v veno ali mišico.
575 mg capsules 
575 mg kapsule
Especially the repeated use of metamizole during breastfeeding must therefore be avoided. 
Zaradi tega se je zlasti ponavljajoči uporabi metamizola med dojenjem treba izogibati.
Adults and adolescents 15 years of age or older 
Odrasli in mladostniki, stari 15 let ali več
This following wording should be reflected in this section. 
V tem poglavju mora biti izraženo naslednje besedilo.
250 mg tablets 
250 mg tablete
There is no experience available with long-term use. 
Z dolgotrajno uporabo ni izkušenj.
In order to minimize the risk of a hypotensive reaction, the intravenous injection must be administered very slowly. 
Da bi kar se da zmanjšali tveganje za hipotenzivno reakcijo, mora biti intravensko injiciranje zelo počasno.
3-11 months intramuscular only 
11 mesecev samo intramuskularno
In animals metamizole induced reproductive toxicity but no teratogenicity (see Section 5.3). 
Pri živalih je metamizol povzročil reproduktivno toksičnost, teratogenosti pa ne (glejte poglavje 5.3).
During the last three months of pregnancy you must not take <invented name> because of an increased risk of complications for the mother and child (haemorrhaging, premature closure of an important vessel, the so-called Ductus Botalli, of the unborn, which naturally closes only after birth). 
V zadnjih treh mesecih nosečnosti zdravila <izmišljeno ime> ne smete jemati, zaradi povečanega tveganja za zaplete pri materi in otroku (krvavitev, prezgodnje zaprtje pomembne žile, t. i. Botallovega voda, pri nerojenem otroku, ki se praviloma zapre šele po rojstvu).
There are only limited data available on the use of metamizole in pregnant women. 
Na voljo je le malo podatkov o uporabi metamizola pri nosečnicah.
To date, there has been insufficient experience with long-term use of metamizole in patients with severe hepatic and renal impairment. 
Do zdaj še ni dovolj izkušenj z dolgotrajno uporabo metamizola pri bolnikih s hudo okvaro jeter ali ledvic.
A. Summary of Product Characteristics 
Povzetek glavnih značilnosti zdravila
If the effect of a single dose is insufficient or later, when the analgesic effect subsides, your doctor may administer another dose up to a daily maximum dose as detailed below. 
Če je učinek posameznega odmerka nezadosten, ali pozneje, ko analgetični učinek izzveni, vam lahko zdravnik da še en odmerek, do največjega dnevnega odmerka, kot je opisano v nadaljevanju.
Maximum daily dose 
Največji dnevni odmerek
Based on published data from pregnant women exposed to metamizole during the first trimester (n=568) no evidence for teratogenic or embryotoxic effects was identified. 
Na podlagi objavljenih podatkov o nosečnicah, ki so bile metamizolu izpostavljene v prvem trimesečju nosečnosti (n = 568), ni mogoče dokazati teratogenih ali embriotoksičnih učinkov.
Use during the third trimester is associated with fetotoxicity (renal impairment and ductus arteriosus constriction) and thus the use of metamizole is contraindicated during the third trimester of pregnancy (see section 4.3). 
Uporaba v tretjem trimesečju je povezana s fetotoksičnostjo (okvara ledvic in konstrikcija arterioznega duktusa), zato je uporaba metamizola v tretjem trimesečju nosečnosti kontraindicirana (glejte poglavje 4.3).
The following dosage scheme for single doses intravenous (except infants below 1 year) or intramuscular should be used as a guide: 
Naslednjo shemo odmerjanja posameznih intravenskih (razen pri dojenčkih, mlajših od 1 leta) ali intramuskularnih odmerkov uporabljajte kot vodilo:
Elderly and patients in poor general health/with renal impairment 
Starejši in bolniki s šibkim splošnim zdravjem/okvaro ledvic
Metamizole crosses the placental barrier. 
Metamizol prehaja skozi posteljico.
The following table shows recommended single doses and maximum daily doses depending on weight or age: 
V naslednji preglednici so prikazani priporočeni posamezni odmerki in največji dnevni odmerki glede na telesno maso in starost:
For all formulations including fixed combination medicinal products: 
Za vse farmacevtske oblike, vključno z zdravili s fiksno kombinacijo:
The breakdown products of metamizole pass into breast-milk in considerable amounts and a risk to the breastfed infant cannot be excluded. 
Razgradni produkti metamizola prehajajo v materino mleko v pomembnih količinah, zato tveganja za dojenega dojenčka ni mogoče izključiti.
In selected cases single doses of metamizole during the first and second trimester might be acceptable when no other treatment options exist. 
V določenih primerih so lahko posamezni odmerki metamizola v prvem in drugem trimesečju sprejemljivi, kadar ne obstaja nobena druga možnost zdravljenja.
Available data on the use of metamizole during the first three months of pregnancy is limited but do not indicate harmful effects to the embryo. 
Na voljo so omejeni podatki o uporabi metamizola v prvem trimesečju nosečnosti, vendar ne nakazujejo škodljivih učinkov za zarodek.
All formulations including fixed combination medicinal products o Do not use X: - if you are in the last three months of pregnancy - if you are breast-feeding 
Za vse farmacevtske oblike, vključno z zdravili s fiksno kombinacijo: o Zdravila X ne uporabljajte: - če ste v zadnjem trimesečju nosečnosti če dojite
Patients with impaired kidney or liver function 
Bolniki z okvaro ledvic ali jeter
In case of inadvertent use of metamizole during the third trimester amniotic fluid and the ductus arteriosus should be controlled by ultrasound and echocardiographia. 
V primeru nenamerne uporabe metamizola v tretjem trimesečju je treba z ultrazvokom in ehokardiografijo spremljati amnijsko tekočino in arteriozni duktus.
However, in general, the use of metamizole during the first and second trimester is not recommended. 
Na splošno pa se uporaba metamizola v prvem in drugem trimesečju ne priporoča.
In case of a single administration of metamizole mothers are advised to collect and discard the breastmilk for 48 hours after the dose. 
V primeru posameznega odmerka metamizola materam svetujemo, da 48 ur po odmerku mleko zbirajo in ga zavržejo.
In children under 1 year of age, metamizole should be injected by the intramuscular route only. 
Pri otrocih, mlajših od 1 leta, se sme metamizol injicirati samo intramuskularno.
• Section 4.2 Posology and method of administration 
• Poglavje 4.2 - Odmerjanje in način uporabe
500 mg/ml oral drops, solution (1 ml = 20 drops) 
500 mg/ml peroralne kapljice, raztopina (1 ml = 20 kapljic)
Amendments to relevant sections of the Product Information 
Spremembe zadevnih poglavij informacij o zdravilu
In children under 1 year of age, <invented name> should be injected by the intramuscular route only. 
Pri otrocih, mlajših od 1 leta, se sme zdravilo <izmišljeno ime> injicirati samo intramuskularno.
Age (body weight) 
Starost (telesna masa)
<Invented name> is not recommended for adolescents less than 15 years and children, as formulations containing less active substance are needed. 
Zdravilo <izmišljeno ime> se ne priporoča pri mladostnikih, mlajših od 15 let, in pri otrocih, saj ti potrebujejo pripravke, ki vsebujejo manj učinkovine.
No dose reduction is required with short-term use only. 
Pri kratkotrajni uporabi odmerka ni treba zmanjšati.
For adults and adolescents 15 years and over (> 53 kg) other strengths or pharmaceutical forms are available. 
Za odrasle in mladostnike, stare 15 let ali več (> 53 kg), so na voljo druge jakosti ali farmacevtske oblike.
In selected cases when no other treatment options exist, single doses of metamizole during the first and second trimester might be acceptable after consultation with your doctor or pharmacist and after the benefits and risks of metamizole use have been carefully weighed up. 
V določenih primerih, kadar ni na voljo drugih možnosti zdravljenja, in po posvetu z vašim zdravnikom ali farmacevtom ter po temeljitem pretehtanju razmerja med koristmi in tveganji lahko morda v prvem in drugem trimesečju nosečnosti vzamete enkratne odmerke metamizola.
* If necessary, the single dose can be increased to 6,2 ml (corresponding to 2,480 mg metamizole) and the daily dose to 12,5 ml (corresponding to 5,000 mg metamizole). 
* Po potrebi se lahko posamezni odmerek poveča na 6,2 ml (kar ustreza 2.480 mg metamizola) in dnevni odmerek na 12,5 ml (kar ustreza 5 000 mg metamizola).
A clear effect is expected 30 to 60 minutes after using the medicine. 
Opazen učinek je mogoče pričakovati v 30 do 60 minutah po uporabi zdravila.
500 mg/ml solution for injection/infusion 
500 mg/ml raztopina za injiciranje/infundiranje
Other pharmaceutical forms/strengths are available which can be appropriately be dosed for smaller children (see section 4.3). 
Na voljo so druge farmacevtske oblike/jakosti, ki jih je pri manjših otrocih mogoče ustrezno odmerjati (glejte poglavje 4.3).
Daily maximum dose kg age capsules capsules 
Največji dnevni odmerek kg starost kapsule kapsule
The dose should be reduced in elderly people, in debilitated patients and in those with reduced renal function, as excretion of the breakdown products of metamizole may be delayed. 
Odmerek je treba zmanjšati pri starejših ljudeh, oslabelih bolnikih in bolnikih z zmanjšanim delovanjem ledvic, saj je lahko izločanje razgradnih produktov metamizola pri njih dolgotrajnejše.
500 mg tablets/capsules (also applicable for 500mg powder for oral solution/effervescent powder/granules for oral solution) 
500 mg tablete/kapsule (velja tudi za 500 mg prašek za peroralno raztopino/šumeči prašek/zrnca za peroralno raztopino)
It is essential to choose the lowest dose that controls pain and fever . 
Treba je izbrati najmanjši odmerek, s katerim je mogoče obvladati bolečino in zvišano telesno temperaturo.
10-12 years (31-45 kg) 
10-12 let (31-45 kg)
As the rate of elimination is reduced in patients with impaired kidney or liver function, repeated high doses should be avoided. 
Ker je hitrost izločanja pri bolnikih z okvaro ledvic ali jeter zmanjšana, se je treba izogibati večkratnim velikim odmerkom.
Use in children and adolescents For the treatment of pain children and adolescents up to 14 years old can take from 8 to 16 mg of <invented name> per kilogram body weight as an individual dose (see table above). 
Uporaba pri otrocih in mladostnikih Za zdravljenje bolečine lahko otroci in mladostniki, stari do vključno 14 let, v posameznem odmerku vzamejo od 8 do 16 mg zdravila <izmišljeno ime> na kilogram telesne mase (glejte preglednico zgoraj).
The maximum daily dose for adults and adolescents over 15 years is 4 suppositories/sachets of effervescent powder (corresponding to 4,000 mg). 
Največji dnevni odmerek pri odraslih in mladostnikih, starih 15 let ali več, so štiri svečke/vrečice šumečega praška (kar ustreza 4.000 mg).
3,450mg (corresponding to 6 capsules) is the maximum daily dose. 
Največji dnevni odmerek je 3.450 mg (kar ustreza 6 kapsulam).
Daily maximum dose kg age tablets /sachets mg tablets/sachets mg 
Največji dnevni odmerek kg starost tablete/vrečice mg tablete/vrečice mg
A clear effect can be expected 30 minutes after parenteral administration. 
Opazen učinek je mogoče pričakovati v 30 minutah po parenteralnem vnosu.
The maximum daily dose is 8 mL; if needed, the daily dose may be increased up to 10 ml (corresponding to 5,000 mg of <invented name>). 
Največji dnevni odmerek je 8 ml; po potrebi se lahko dnevni odmerek poveča do 10 ml (kar ustreza 5.000 mg zdravila <izmišljeno ime>).
The lowest dose needed to control pain and fever should always be selected. 
Vedno je treba izbrati najmanjši odmerek, ki je potreben za obvladovanje bolečine in zvišane telesne temperature.
4-6 years (19-23 kg) 
4-6 let (19-23 kg)
13-14 years (46-53 kg) 
13-14 let (46-53 kg)
Paediatric population <Invented name> is contraindicated in infants below the age of 3 months or below 5 kg of body weight (see section 4.3). 
Zdravilo <izmišljeno ime> je kontraindicirano pri dojenčkih, mlajših od 3 mesecev, ali s telesno maso manj kot 5 kg (glejte poglavje 4.3).
<12 months 1-5 1-3 years 
< 12 mesecev 1-5 1-3 leta
However, in general the use of metamizole during the first and second trimester is not recommended. 
Vendar pa se na splošno uporaba metamizola v prvem in drugem trimesečju nosečnosti odsvetuje.
<12 months 1-3 1-3 years 
< 12 mesecev 1-3 1-3 leta
The maximum daily dose is 10,0 mL; if needed, the daily dose may be increased up to 12,5 ml (corresponding to 5,000 mg of <invented name>). 
Največji dnevni odmerek je 10,0 ml; po potrebi se lahko dnevni odmerek poveča do 12,5 ml (kar ustreza 5.000 mg zdravila <izmišljeno ime>).
Other pharmaceutical forms/strengths are available which can be appropriately dosed for infants below the age of 3 months. 
Na voljo so druge farmacevtske oblike/jakosti, ki jih je pri dojenčkih, mlajših od 3 mesecev, mogoče ustrezno odmerjati.
7-9 years (24-30 kg) 
7-9 let (24-30 kg)
300 mg suppository 
300 mg svečka
<invented name> should not be used for children younger than 15 years of age. 
Zdravila <izmišljeno ime> ne smete uporabljati pri otrocih, mlajših od 15 let.
Daily maximum dose kg age tablets tablets 
Največji dnevni odmerek kg starost tablete tablete
Other forms and strengths of this medicine are available for younger children; ask your doctor or pharmacist. 
Za mlajše otroke so na voljo druge oblike in jakosti; posvetujte se z zdravnikom ali farmacevtom.
Other forms and strengths of this medicine are available for younger infants; ask your doctor or pharmacist. 
Za mlajše dojenčke so na voljo druge oblike in jakosti; posvetujte se z zdravnikom ali farmacevtom.
The dose should be reduced in elderly people, in debilitated patients and in those with reduced creatinine clearance, as elimination of the metabolic products of metamizole may be prolonged. 
Starejša populacija, oslabeli bolniki in bolniki z zmanjšanim očistkom kreatinina Pri starejših ljudeh, oslabelih bolnikih in bolnikih z zmanjšanim očistkom kreatinina je treba odmerek zmanjšati, saj je lahko izločanje presnovnih produktov metamizola pri njih podaljšano.
In the case of fever, a dose of 10 mg metamizole per kilogram body weight is generally sufficient for children. 
Ob zvišani telesni temperaturi pri otrocih na splošno zadostuje odmerek 10 mg metamizola na kilogram telesne mase.
4,000 mg (corresponding to 8 tablets/sachets) is the maximum daily dose. 
Največji dnevni odmerek je 4.000 mg (kar ustreza 8 tabletam/vrečicam).
As the elimination rate is reduced when renal or hepatic function is impaired, multiple high doses should be avoided. 
Ker se ob okvari jeter ali ledvic hitrost izločanja zmanjša, se je treba izogibati večkratnim velikim odmerkom.
<Invented name> is not recommended for infants below the age of 3 months. 
Zdravilo <izmišljeno ime> se ne priporoča pri dojenčkih, mlajših od 3 mesecev.
<invented name> should not be given to children under 3 months of age. 
Zdravilo <izmišljeno ime> se ne sme dajati otrokom, mlajšim od 3 mesecev.